BioAge Labs (NASDAQ:BIOA) Shares Gap Up – Should You Buy?

BioAge Labs, Inc. (NASDAQ:BIOA)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $18.27, but opened at $19.44. BioAge Labs shares last traded at $18.6450, with a volume of 201,341 shares traded.

Wall Street Analyst Weigh In

BIOA has been the subject of several recent analyst reports. Citigroup raised their target price on BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday. Piper Sandler started coverage on BioAge Labs in a research report on Tuesday. They issued an “overweight” rating on the stock. Finally, Wall Street Zen cut BioAge Labs from a “hold” rating to a “sell” rating in a research note on Monday. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $15.00.

BioAge Labs Stock Performance

The stock’s 50 day moving average price is $14.29 and its 200-day moving average price is $8.58.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.11. The business had revenue of $2.05 million for the quarter.

Insider Buying and Selling

In other BioAge Labs news, insider Paul D. Rubin sold 68,897 shares of the business’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $10.19, for a total transaction of $702,060.43. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Dov A. Md Goldstein sold 27,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total value of $531,900.00. Following the completion of the sale, the chief financial officer owned 22,408 shares in the company, valued at approximately $441,437.60. This represents a 54.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 347,004 shares of company stock worth $5,673,859 in the last 90 days. Insiders own 20.82% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Public Employees Retirement System of Ohio acquired a new position in BioAge Labs during the second quarter worth $57,000. Geode Capital Management LLC increased its stake in BioAge Labs by 60.8% during the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock worth $1,873,000 after buying an additional 171,426 shares in the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of BioAge Labs during the second quarter valued at approximately $27,000. Intech Investment Management LLC purchased a new position in shares of BioAge Labs in the second quarter valued at approximately $60,000. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of BioAge Labs in the second quarter worth approximately $206,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.